Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Brenscocatib

Phase Two

Phase Two

Therapeutic Approach

Anti-Inflammatory

Brenscocatib is an oral drug designed to block the function of enzymes, such as neutrophil elastase, that play an essential role in inflammation. When the lungs are infected with bacteria, white blood cells release these enzymes, including neutrophil elastase, to fight the infection. In CF, these enzymes can result in excessive inflammation that causes damage to the lungs. Brensocatib may decrease this damage by inhibiting neutrophil elastase and decreasing inflammation in the lungs.

Status

A phase 2 study to test the safety of brensocatib in adults with CF is underway.

Sponsor

This program is sponsored by Insmed.



Contact us about Brenscocatib >